Intellia Therapeutics, Inc.(NTLA)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
NTLA | 1.66 B | - | -46.20% | 0.00% | -$3.35 | -55.44% | 0.10x | 0.00% | $28.25 | $7.95 |
VRDN | 2.54 B | - | 278.70% | 0.00% | -$3.39 | -65.74% | 0.37x | 0.00% | $34.29 | $13.18 |
IMNM | 2.11 B | - | - | 0.00% | -$2.52 | -64.03% | 0.01x | 0.00% | $30.06 | $14.64 |
BCRX | 2.03 B | - | 33.60% | -40.90% | -$1.40 | - | - | 0.00% | $11.22 | $6.23 |
RARE | 1.58 B | - | 28.10% | -81.73% | -$5.82 | - | - | 0.00% | $39.89 | $12.73 |
Peer Valuation & Performance Analysis
Peer group analysis for Intellia Therapeutics, Inc. (NTLA) compared to its primary competitors (including VRDN, IMNM, BCRX) reveals distinct metrics. NTLA trades at a valuation premium compared to its competitors, with a P/E ratio of -3.5x versus the peer average of -5.5x (representing a -36% premium). This indicates that the market expects superior growth or commands a quality premium for NTLA. In terms of growth, NTLA's revenue growth of -46.2% lags behind the peer average of 113.5%, indicating potential market share losses or slower industry adoption. Additionally, it boasts superior profitability with a net margin of 0.0% compared to the peer average of -30.7%, demonstrating strong cost controls and pricing power.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• NTLA ranks #0 in P/E ratio, #4 in revenue growth, and #1 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-20 | $11.43 | $11.99 | $11.28 | $11.84 | 3,391,626 | +2.25% |
| 2026-10-19 | $11.54 | $11.85 | $11.33 | $11.58 | 3,503,900 | +1.40% |
| 2026-10-16 | $11.60 | $11.68 | $10.91 | $11.42 | 8,235,600 | +0.71% |
| 2026-10-15 | $11.33 | $11.82 | $11.10 | $11.34 | 6,519,700 | -0.79% |
| 2026-10-14 | $11.83 | $11.87 | $11.29 | $11.43 | 5,439,200 | -4.03% |
| 2026-10-13 | $12.30 | $12.48 | $11.81 | $11.91 | 5,177,200 | -5.33% |
| 2026-10-12 | $13.08 | $13.23 | $12.56 | $12.58 | 4,380,500 | -3.75% |
| 2026-10-09 | $12.36 | $13.27 | $11.93 | $13.07 | 8,154,700 | +3.73% |
| 2026-10-08 | $11.90 | $12.64 | $11.76 | $12.60 | 13,974,100 | +7.60% |
| 2026-10-07 | $12.08 | $12.41 | $11.70 | $11.71 | 8,298,200 | -5.34% |
| 2026-10-06 | $12.50 | $13.22 | $12.04 | $12.37 | 7,949,100 | -2.98% |
| 2026-10-05 | $12.35 | $12.88 | $11.85 | $12.75 | 4,962,800 | +4.00% |
| 2026-10-02 | $12.42 | $12.77 | $12.10 | $12.26 | 4,501,800 | +1.16% |
| 2026-10-01 | $11.98 | $12.65 | $11.82 | $12.12 | 7,445,400 | +0.50% |
| 2026-09-30 | $11.96 | $12.23 | $11.75 | $12.06 | 5,314,800 | +0.25% |
Explore More Analysis for NTLA
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.